NasdaqGM:AUPHBiotechs
Aurinia Pharmaceuticals Acquisition Of Kezar Reshapes Autoimmune Growth And Risks
Aurinia Pharmaceuticals, ticker NasdaqGM:AUPH, has agreed to acquire Kezar Life Sciences to expand its autoimmune disease portfolio.
The deal includes Kezar’s clinical candidate zetomipzomib and has received approval from Kezar’s board.
The transaction is expected to close soon, pending remaining customary conditions.
Aurinia Pharmaceuticals enters this deal with its shares at $15.79 and a 1 year return of 119.3%. Over shorter periods, the stock has seen returns of 6.5% over the past week...